Medtronic ($MDT) has issued repeated warnings about its SynchroMed line of implanted infusion pumps, detailing problems that have led to 14 deaths since 1996. But despite those concerns, doctors and patients told the Minneapolis Star-Tribune that SynchroMed's benefits still outweigh its risks, and many are holding tight until problems with their specific implants arise. Article